Drug intelligence / Profile preview

I-Cross

Development stage
Phase 3
Lead developer
Sooft Italia
Modality
Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Ophthalmic
01

Overview

I-Cross is a lubricating ophthalmic solution (artificial tear) composed of cross-linked sodium hyaluronate (typically 0.20%). Unlike traditional linear hyaluronic acid, the cross-linked form of hyaluronate in I-Cross offers significantly higher viscoelasticity and mucoadhesiveness, making it more resistant to enzymatic degradation by hyaluronidase. This allows the solution to form a more stable and persistent protective film on the ocular surface, effectively stabilizing the tear film and providing prolonged relief from symptoms of moderate to severe dry eye (keratoconjunctivitis sicca). It is frequently used to manage chronic ocular surface irritation, environmental stress, or post-operative recovery, such as following refractive or cataract surgery.

Brand names
I-CrossIcross
Other names
Cross-linked sodium hyaluronateCross-linked hyaluronic acidI-Cross 0.2%
02

Targets

Ocular surface mucin-glycocalyx matrixCD44 (CD44 antigen)

Beyond the preview

Go deeper on I-Cross.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on I-Cross.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call